Search
Synthetic Conjugated Estrogens, B
go.drugbank.com/drugs/DB09318ApprovedPrior to menopause, the primary source of estrogen is the ovarian follicle, which secretes 70-500 micrograms of estradiol daily, depending on the phase of the menstrual cycle. … Estrogens act by binding to estrogen receptors on a wide variety of tissues in the body and modulating the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone
Tinoridine
go.drugbank.com/drugs/DB13001InvestigationalTinoridine is under investigation in clinical trial NCT01224756 (Efficacy of Tinoridine in Treating Pain and Inflammation in Adults).
Categories: Analgesics, Non-Narcotic, Anti-Inflammatory Agents, Non-SteroidalMetiamide
go.drugbank.com/drugs/DB08805ExperimentalIt was an intermediate product on the path to developing cimetidine.
Embusartan
go.drugbank.com/drugs/DB19949ExperimentalThe usage of the INN stem '-sartan' in the name indicates that Embusartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).
Categories: Agents Acting on the Renin-Angiotensin SystemEstradiol benzoate
go.drugbank.com/drugs/DB13953ApprovedVet approvedWithdrawneffects within the body through binding to the Estrogen Receptor (ER) including ERα and ERβ subtypes, which are located in various tissues including in the breasts, uterus, ovaries, skin, prostate, bone … [DB00783] is commonly produced with an ester side-chain as endogenous estradiol has very low oral bioavailability on its own (2-10%).
Bronopol
go.drugbank.com/drugs/DB13960ApprovedL4873] and in other products where it may not primarily be used in the role of a non-medicinal preservative antimicrobial [L4874]. … Nevertheless, ongoing contemporary re-evaluations of bronopol use in large markets such as Canada now place various compositional and product restrictions on the use of the agent in cosmetic products [
Cetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A227963,L39045] It has also been investigated in advanced colorectal cancer, EGFR-expressing non-small cell lung cancer (NSCLC), and unresectable squamous cell skin cancer.
Temozolomide
go.drugbank.com/drugs/DB00853ApprovedInvestigational[L32033] Temozolomide was granted FDA approval on August 11, 1999, as an oral capsule and subsequently on February 27, 2009, as an intravenous injection. … [A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases